SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-23-007357
Filing Date
2023-11-30
Accepted
2023-11-30 09:04:45
Documents
12
Period of Report
2023-11-30
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_113023.htm   iXBRL 8-K 20929
  Complete submission text file 0001171843-23-007357.txt   193211

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bcrx-20231130.xsd EX-101.SCH 3039
3 XBRL LABEL FILE bcrx-20231130_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE bcrx-20231130_pre.xml EX-101.PRE 22375
6 EXTRACTED XBRL INSTANCE DOCUMENT f8k_113023_htm.xml XML 3302
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 231454085
SIC: 2836 Biological Products, (No Diagnostic Substances)